Drug
Dolutegravir Sodium And Lamivudine
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Product Dose Omission In Error | 224 | 50.0 | 53.3 | signal |
| 2 | Intentional Dose Omission | 109 | 23.8 | 24.5 | signal |
| 3 | Product Dose Omission Issue | 1,093 | 22.9 | 32.7 | signal |
| 4 | Anhedonia | 92 | 20.7 | 21.2 | signal |
| 5 | Osteopenia | 38 | 14.8 | 15.0 | signal |
| 6 | Inability To Afford Medication | 17 | 10.3 | 10.3 | signal |
| 7 | Treatment Noncompliance | 89 | 9.7 | 10.0 | signal |
| 8 | Neurotoxicity | 26 | 8.9 | 9.0 | signal |
| 9 | Inappropriate Schedule Of Product Administration | 256 | 8.6 | 9.2 | signal |
| 10 | Osteoporosis | 58 | 8.4 | 8.5 | signal |
| 11 | Bone Density Decreased | 41 | 7.7 | 7.8 | signal |
| 12 | Helicobacter Infection | 12 | 7.0 | 7.0 | signal |
| 13 | Extra Dose Administered | 46 | 6.9 | 6.9 | signal |
| 14 | Product Use Issue | 195 | 6.2 | 6.5 | signal |
| 15 | Vitamin D Deficiency | 10 | 6.1 | 6.1 | signal |
| 16 | Adverse Drug Reaction | 89 | 5.9 | 6.0 | signal |
| 17 | Glomerular Filtration Rate Decreased | 12 | 5.9 | 5.9 | signal |
| 18 | Hepatitis C | 11 | 5.4 | 5.4 | signal |
| 19 | Nephropathy | 8 | 5.1 | 5.1 | signal |
| 20 | Economic Problem | 13 | 5.0 | 5.0 | signal |
| 21 | Emotional Distress | 102 | 5.0 | 5.1 | signal |
| 22 | Chronic Kidney Disease | 61 | 4.7 | 4.8 | signal |
| 23 | Foot Fracture | 15 | 4.7 | 4.7 | signal |
| 24 | Depressed Mood | 41 | 4.6 | 4.7 | signal |
| 25 | Renal Impairment | 60 | 4.3 | 4.3 | signal |
| 26 | Dysstasia | 20 | 4.1 | 4.1 | signal |
| 27 | Exposure During Pregnancy | 41 | 3.9 | 4.0 | signal |
| 28 | Secretion Discharge | 8 | 3.8 | 3.9 | signal |
| 29 | Illness | 64 | 3.8 | 3.8 | signal |
| 30 | Abortion Induced | 6 | 3.8 | 3.8 | signal |
| 31 | Brain Fog | 9 | 3.7 | 3.7 | signal |
| 32 | Splenomegaly | 7 | 3.6 | 3.6 | signal |
| 33 | Wrist Fracture | 7 | 3.5 | 3.5 | signal |
| 34 | Proteinuria | 11 | 3.5 | 3.5 | signal |
| 35 | Erectile Dysfunction | 15 | 3.5 | 3.5 | signal |
| 36 | Peripheral Coldness | 8 | 3.5 | 3.5 | signal |
| 37 | Nightmare | 20 | 3.4 | 3.4 | signal |
| 38 | Gastritis | 15 | 3.4 | 3.4 | signal |
| 39 | Renal Pain | 6 | 3.4 | 3.4 | signal |
| 40 | Blood Triglycerides Increased | 10 | 3.4 | 3.4 | signal |
| 41 | Decreased Activity | 6 | 3.3 | 3.3 | signal |
| 42 | Tooth Fracture | 6 | 3.2 | 3.2 | signal |
| 43 | Anxiety | 155 | 3.2 | 3.3 | signal |
| 44 | Multiple Fractures | 9 | 3.2 | 3.2 | signal |
| 45 | Transaminases Increased | 12 | 3.2 | 3.2 | signal |
| 46 | Injection Site Induration | 7 | 3.2 | 3.2 | signal |
| 47 | Quality Of Life Decreased | 7 | 3.1 | 3.1 | signal |
| 48 | Product Administration Error | 10 | 3.0 | 3.0 | signal |
| 49 | Tuberculosis | 6 | 2.8 | 2.8 | signal |
| 50 | Bipolar Disorder | 5 | 2.7 | 2.7 | no signal |
| 51 | Osteonecrosis | 15 | 2.7 | 2.7 | signal |
| 52 | Incorrect Dose Administered | 98 | 2.6 | 2.6 | signal |
| 53 | Renal Injury | 13 | 2.6 | 2.6 | signal |
| 54 | Drug Resistance | 11 | 2.5 | 2.6 | signal |
| 55 | Lower Limb Fracture | 8 | 2.5 | 2.5 | signal |
| 56 | Therapy Change | 4 | 2.5 | 2.5 | no signal |
| 57 | Face Oedema | 7 | 2.5 | 2.5 | signal |
| 58 | Bone Loss | 6 | 2.3 | 2.4 | no signal |
| 59 | Foetal Exposure During Pregnancy | 32 | 2.3 | 2.4 | signal |
| 60 | Skeletal Injury | 4 | 2.3 | 2.3 | no signal |
| 61 | Therapeutic Response Unexpected | 17 | 2.2 | 2.3 | signal |
| 62 | Musculoskeletal Disorder | 7 | 2.2 | 2.2 | no signal |
| 63 | Cytomegalovirus Infection | 6 | 2.1 | 2.1 | no signal |
| 64 | Abnormal Dreams | 10 | 2.1 | 2.1 | signal |
| 65 | Hospitalisation | 54 | 2.1 | 2.1 | signal |
| 66 | Suicidal Ideation | 32 | 2.1 | 2.1 | signal |
| 67 | Premature Baby | 10 | 2.0 | 2.0 | no signal |
| 68 | Sars-cov-2 Test Positive | 4 | 1.8 | 1.8 | no signal |
| 69 | Abortion Spontaneous | 12 | 1.8 | 1.8 | no signal |
| 70 | Toxic Skin Eruption | 3 | 1.8 | 1.8 | no signal |
| 71 | Circumstance Or Information Capable Of Leading To Medication Error | 9 | 1.6 | 1.6 | no signal |
| 72 | Neoplasm Malignant | 17 | 1.5 | 1.5 | no signal |
| 73 | Injection Site Discolouration | 3 | 1.4 | 1.4 | no signal |
| 74 | Product Complaint | 6 | 1.4 | 1.4 | no signal |
| 75 | Injection Site Mass | 5 | 0.8 | 0.8 | no signal |
| 76 | Renal Cancer | 5 | 0.6 | 0.6 | no signal |
| 77 | Gynaecomastia | 3 | 0.6 | 0.6 | no signal |
| 78 | Myelosuppression | 3 | 0.5 | 0.5 | no signal |
| 79 | Prostate Cancer | 5 | 0.4 | 0.4 | no signal |